Compare FINV & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | NNNN |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | China | Germany |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 2025 |
| Metric | FINV | NNNN |
|---|---|---|
| Price | $5.17 | $27.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $11.55 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 26.9K |
| Earning Date | 11-19-2025 | 04-28-2026 |
| Dividend Yield | ★ 5.44% | N/A |
| EPS Growth | ★ 27.76 | N/A |
| EPS | ★ 1.50 | 0.06 |
| Revenue | ★ $1,969,555,571.00 | $8,185,146.00 |
| Revenue This Year | $5.54 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $3.51 | $534.57 |
| Revenue Growth | 8.81 | ★ 21.95 |
| 52 Week Low | $4.70 | $5.18 |
| 52 Week High | $11.08 | $55.65 |
| Indicator | FINV | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 48.35 |
| Support Level | $5.12 | $26.89 |
| Resistance Level | $5.40 | $44.73 |
| Average True Range (ATR) | 0.21 | 5.78 |
| MACD | 0.07 | -0.21 |
| Stochastic Oscillator | 42.31 | 29.62 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.